People · Operator
Named in public records as an officer, director or promoter · active 2016–2018 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vividion Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.7M | $4.5B | 2016 |
| Cardinal Analytx, Inc. | — | Other Technology | Series B | $39.7M | $65.2M | 2017 |
John K. Park at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John K. Park on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John K. Clarke | 2 | 5 |
| Mark Smith | 1 | 28 |
| JOHN DOERR | 1 | 14 |
| THOMAS MCKINLEY | 1 | 5 |
| John Park | 1 | 5 |
| Kent Marquardt | 1 | 3 |
| Thomas G. McKinley | 1 | 3 |
| Patricia L. Allen | 1 | 3 |
| Nigam Shah | 1 | 3 |
| Jeffrey Hatfield | 1 | 2 |
| Kristina K. Burow | 1 | 2 |
| John L Clarke | 1 | 2 |
| Linda Hand | 1 | 2 |
| Kristina L. Burow | 1 | 2 |
| Thomas E. Daniel | 1 | 1 |
| Thomas E. Woiwode | 1 | 1 |
| Jakob E. Loven | 1 | 1 |
| Diego K. Miralles | 1 | 1 |
| Fred K. Aslan | 1 | 1 |
| Jakob K. Loven | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.